Pharmaceuticals & Biotech U.S. Community

I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.

Catalysts Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u $22,999.80 Ingrezza@ Ingrezza (valbenazine) costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength. INGREZZA Capsule 40 MG $310.80 INGREZZA SPRINKLE Capsule 40 MG $310.80 Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Catalysts Most Immediate Catalysts (1–2 Years) Resilient Demand for Life Sciences & Diagnostics – TMO is a key supplier for biotech, pharma, and research institutions, ensuring steady demand despite economic cycles. Cost Synergies from PPD Acquisition – The 2021 acquisition of PPD (clinical research services) is expected to enhance revenue synergies and margin expansion.

*DISCLAIMER: *This article is NOT financial advice of any kind, i am NOT a financial adviser, this content should NOT be construed as an offer, recommendation or inducement to buy or sell Greenwich Lifesciences $GLSI stock. Do yor own Due diligence with this type of products before taking from granted any of these opinions.

Catalysts ◦ Strong position in the GLP-1 drug market , leading with Ozempic for diabetes and Wegovy for obesity. These products have driven significant growth.

Geron Corporation has announced that the European Commission has granted marketing authorization for RYTELO (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (LR-MDS). Key Highlights: - RYTELO is the first and only telomerase inhibitor approved in the U.S. and Europe for LR-MDS.

Coherus is a promising company that did a bad borrowing and has more than paid the price. Its convertible bondholders created a short hedge and have inflicted massive damage on the company's SP.

Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.

1. Cybin's Intellectual Property : Cybin has over 70 granted patents and 220 patent applications pending across multiple patent families.